托巴比塔尔在快溶剂中的固态稳定性:对溶解行为和儿科配方性能的影响
Aurélien Freisz1, Imen Dhifallah2, Philip Chennell3
1CHU Clermont-Ferrand, Pôle Pharmacie, 63003, Clermont-Ferrand, France.
Pharmaceutical research
|March 3, 2026
概括
冷储存对于维持儿科镇静剂托巴比特 suppositories 的稳定性至关重要. 这确保药物保持溶解和有效的程序护理,而不是冷藏储存,导致沉.
科学领域:
- 制药科学 制药科学
- 儿科药理学 儿科药理学
- 配方稳定性 配方稳定性
背景情况:
- 安全有效的镇静剂配方对于儿科手术护理至关重要.
- 多巴比塔尔是一种广泛使用的儿科镇静剂,但口服受限于口感.
- 如果保证配方的稳定性,巴比塔尔假药的直肠给药提供了一个替代方案.
研究的目的:
- 评估用于儿科的快速溶解巴比他的物理化学和微生物稳定性.
- 为了确定储存条件 (冷藏或冷) 和氧化 (NaOH) 度对体稳定性的影响.
- 为了评估型的长期保存.
主要方法:
- 用于配制具有不同NaOH度的 pentobarbital suppositories的配方.
- 在5°C (冷藏) 和-20°C (冷) 的温度下保存,最长180天.
- 通过宏观检查,pH值,溶解,机械强度,软化时间,微生物质量,拉曼光谱和X射线衍射来评估稳定性.
主要成果:
- 冰箱储存 (5°C) 诱导了巴比特沉,降低了pH值,并转化为自由酸,导致90天后不完全溶解.
- 在整个研究期间,冷储存 (-20°C) 保持了体的完整性,pH值和完全溶解.
- 即使在解和随后在5°C储存30天后,冷假药也保持稳定;增加的NaOH延迟了5°C的不稳定性,但没有阻止它.
- 所有配方都符合药库的机械和微生物学标准.
结论:
- 储存温度是影响巴比他体稳定性的主要因素,冷可以确保长期保存.
- 氧化缓冲有助于减轻配方问题,并延迟药物的降解,延长保质期.
- 这些发现支持进一步开发和临床评估用于儿科镇静的巴比塔尔假药.
相关概念视频
Factors Influencing Drug Absorption: Pharmaceutical Parameters
835
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
835
Factors Influencing Drug Absorption: Drug Dissolution
1.8K
The pharmacokinetic journey of drugs from solid oral dosage forms into systemic circulation is multifaceted. It begins with disintegration, a prerequisite ensuring a solid dosage form's subdivision into minute particles. Dissolution occurs next as these granulated entities solubilize in gastrointestinal fluids. This solubilization is crucial for the succeeding stage, permeation, which describes the traversal of the drug across the intestinal membrane and its subsequent entry into the blood...
1.8K
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
887
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
887
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
226
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
226
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
421
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
421
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
975
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
975


